A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

8.3K views

⸱

DOI:

10.3791/54720

⸱

November 8th, 2016

 ,  ,  , 

In This Article

Summary

We present here a method to develop functional antigen (Ag)-specific regulatory T cells (Tregs) from induced pluripotent stem cells (iPSCs) for immunotherapy of autoimmune arthritis in a murine model.

Abstract

Autoimmune diseases arise due to the loss of immunological self-tolerance. Regulatory T cells (Tregs) are important mediators of immunologic self-tolerance. Tregs represent about 5 - 10% of the mature CD4+ T cell subpopulation in mice and humans, with about 1 - 2% of those Tregs circulating in the peripheral blood. Induced pluripotent stem cells (iPSCs) can be differentiated into functional Tregs, which have a potential to be used for cell-based therapies of autoimmune diseases. Here, we present a method to develop antigen (Ag)-specific Tregs from iPSCs (i.e., iPSC-Tregs). The method is based on incorporating the transcription factor FoxP3 and an Ag-specific T cell receptor (TCR) into iPSCs and then differentiating on OP9 stromal cells expressing Notch ligands delta-like (DL) 1 and DL4. Following in vitro differentiation, the iPSC-Tregs express CD4, CD8, CD3, CD25, FoxP3, and Ag-specific TCR and are able to respond to Ag stimulation. This method has been successfully applied to cell-based therapy of autoimmune arthritis in a murine model. Adoptive transfer of these Ag-specific iPSC-Tregs into Ag-induced arthritis (AIA)-bearing mice has the ability to reduce joint inflammation and swelling and to prevent bone loss.

Introduction

Autoimmune arthritis is a systemic disease characterized by hyperplasia of synovial tissue and progressive destruction of articular cartilage, bone, and ligaments1. The defective generation or function of Tregs in autoimmune arthritis contributes to chronic inflammation and tissue injury because Tregs play a crucial role in preventing the development of auto-reactive immune cells.

Manipulation of Tregs is an ideal strategy for the development of therapies to suppress inflammation in an Ag-dependent manner. For Treg-based immunotherapy, the specificity of the transferred Tregs is important for the treatment of ongoing autoimmunit....

Access restricted. Please log in or start a trial to view this content.

Protocol

All animal experiments are approved by the Pennsylvania State University College of Medicine Animal Care Committee (IACUC protocol #45470) and are conducted in compliance with the guidelines of the Association for the Assessment and Accreditation of Laboratory Animal Care.

1. Stem Cell Culture

  1. Incubate a 10 cm dish with 10 ml of 0.1% gelatin for at least 30 min at 37 °C (incubator) in order to coat the plate.
  2. Remove gelatin from the dish and plate 3 x 106 irradiated SNL76/7 cells and incubate for one day at 37 °C (incubator) using 10% DMEM media (10% FBS and 1% penicillin streptomycin).
  3. R....

Access restricted. Please log in or start a trial to view this content.

Results

As shown here, on day 28, Ag-specific Tregs substantially expressed CD3 and Ag-specific TCR, two T cell markers. The CD3+TCRVβ5+ population expressed CD4. Most of the CD3+TCRVβ5+CD4+ cells also expressed CD25, CD127, and CTLA-4, which are typically expressed at elevated levels in naturally occurring Tregs (nTregs) and in T cells expressing FoxP3 ectopically. FoxP3 expression in iPSC-derived cells persisted even after long-t.......

Access restricted. Please log in or start a trial to view this content.

Discussion

In this protocol, a critical step is the in vitro differentiation of TCR/FoxP3 gene-transduced iPSCs. In vitro Notch signaling induces development towards the T cell lineage. To differentiate iPSCs into CD4+FoxP3+ Tregs, we used the OP9-DL1/DL4/I-Ab cells, which highly express MHC II (I-Ab) molecules. Most of the iPSCs differentiate into CD4+ cells. However, after the surface TCR expression, many differentiated pre-T cells lose the ability to differ.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This project was funded, in part, under grants from the National Institutes of Health (R01AI121180, R21AI109239 and K18CA151798), the American Diabetes Association (1-16-IBS-281), and the Pennsylvania Department of Health (Tobacco Settlement Funds) to J.S.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
C57BL/6j miceJackson Laboratory664
B6.129S7 Rag1tm1Mom/JJackson Laboratory2216
Anti-CD3 (2C11) antibodyBD Pharmingen553058
Anti-CD28 (37.51) antibodyBD Pharmingen553295
Anti-CD4 (GK1.5) antibodyBiolegend100417
Anti-CD8 (53–6.7) antibodyBiolegend100714
Anti-CD25 (3C7) antibodyBiolegend101912
Anti-TCR-β (H57597) antibodyBiolegend109220
Anti-IL10Biolegend505010
Anti-TGFβBiolegend141402
DMEMInvitrogenABCD1234
α-MEMInvitrogenA10490-01
FBSHycloneSH3007.01
Brefeldin ASigmaB7651
PolybreneSigma107689
GenejammerIntegrated science204130
ACK Lysis bufferLonza10-548E
mFlt-3Lpeprotech250-31L
mIL-7peprotech217-17
GelatinSigmaG9391
ParaformaldehydeSigmaP6148-500GCaution: Allergenic, Carcenogenic, Toxic
Permeabilization bufferBiolegend421002
mBSASigmaA7906
Ova albuminAvantor0440-01
CFADifco2017014
Tailveiner restrainerBraintree scientificRTV 150-STD

References

  1. Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature. 423, 356-361 (2003).
  2. Ferraro, A., et al. Interindividual variation in human T regulatory cells. Proc Natl Acad Sci U S A. 111, E1111-E1120 (2014).
  3. Tang, Q., et al.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Stem Cell-derived TregsAntigen-specific TregsiPSC DifferentiationOP9 Stromal CellsFoxP3 ExpressionTCR TransductionAdoptive TransferAutoimmune ArthritisJoint InflammationBone Loss